This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Sensitive determination of the pharmacokinetics of PEGylated molecules can accelerate the process of drug development. Here,
we combined different anti-PEG Fab expressing 293T cells as capture cells (293T/3.3, 293T/6.3, and 293T/15-2b cells) with four
detective anti-PEG antibodies (3.3, 6.3, 7A4, or 15-2b) to optimize an anti-PEG cell-based sandwich ELISA. Then, we quantified
free PEG (mPEG2K-NH2 and mPEG5K-NH2) or PEG-conjugated small molecules (mPEG5K-biotin and mPEG5K-NIR797), proteins
(PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots). The combination of 293T/15-2b cells and
the 7A4 detection antibody showed best sensitivity for free PEG, PEG-like molecules, and PEGylated proteins with detection at ng
mL−1 levels. On the other hand, 293T/3.3 cells combined with the 15-2b antibody had the highest sensitivity for quantifying Lipo-Dox
at 2 ng mL−1. All three types of anti-PEG cells combined with the 15-2b antibody had high sensitivity for quantum dot quantification
down to 7 pM. These results suggest that the combination of 293T/15-2b cells and 7A4 detection antibody is the optimal pair for
sensitive quantification of free PEG, PEG-like molecules, and PEGylated proteins, whereas the 293T/3.3 cells combined with 15-
2b are more suitable for quantifying PEGylated nanoparticles. The optimized anti-PEG cell-based sandwich ELISA can provide a
sensitive, precise, and convenient tool for the quantification of a range of PEGylated molecules.
Wen-Wei Lin received BS degree in 2009 from Kaohsiung Medical University, Taiwan, with a major in Biomedical Science and Environmental Biology. He received MSc degree in 2011 from the Graduate Institute of Oral Biology at National Taiwan University. He is currently a PhD student at the Institute of Biomedical Sciences in National Sun Yat-sen University, working in the laboratory of Prof. Tian-Lu Cheng for development of antibody drugs. His research interest is antibody engineering, targeted therapy of cancer and drug discovery.